Office of Medical Communications

Members of the Vaccine Testing Center and the International Centre for Diarrheal Disease Research, Bangladesh

(SEPTEMBER 30, 2023) The Vaccine Testing Center, led by Beth Kirkpatrick, M.D., professor and chair of microbiology and molecular genetics and professor of medicine, is working with the International Centre for Diarrheal Disease Research, Bangladesh on a promising tetravalent dengue vaccine in Bangladesh, according to The Daily Star (Dhaka, Banglasdesh).

Their work, evaluating the single-dose tetravalent dengue vaccine candidate TV005, demonstrated safety and immune responsiveness in children and adults. The accompanying study was recently published in the journal The Lancet Infectious Diseases.

“The TV005 vaccine is the only single-dose tetravalent dengue vaccine, which is an important feature of this vaccine,” Kirkpatrick said. “It also appears to prompt immune responses to all four of the dengue serotypes, which is important for any tetravalent dengue vaccine.” Investigators from UVM and ICDDR,B share the hope that the information is useful to Bangladesh and the large populations of South Asia.

This work has also been covered by The Daily Sun (Bangladesh), The St Kitts Nevis Observer, The Business Standard, The Dhaka Tribune, The Daily Observer, and Bangladesh Sangbad Sangstha, among other media outlets.